glp 1 and cannabinoids GLP-1 medications get at the heart of addiction: study – WashU Medicine IUPHAR review – Glucagon-like peptide-1

: ,

Brown fat biology and thermogenesis

When Genetic Predisposition Matters: GLP-1 Pathway Variants and Treatment Response Recent genomics research shows variants in the glucose-dependent insulinotropic polypeptide receptor (GIPR rs1800437), and metabolic genes like FTO (rs9939609) and MC4R (rs17782313) correlate with differential weight loss and glucose control on incretin-based therapies

Among the rare ocular side effects of GLP-1RAs is non-arteritic anterior ischemic optic neuropathy (NAION), which can cause permanent loss of vision, states the report, Glucagon-like Peptide-1 Receptor Agonists and Ocular Health: Guidance for Optometric Practice. The report was first presented at the 2025 Optometry's Meeting | 5th World Congress of Optometry and is meant to provide critical guidance to doctors of optometry treating patients on GLP-1RAs

However, it will almost certainly require a stringent prior authorization process

A $199 plan can quietly become a $349 plan months later as you titrate toward your maintenance dose, a roughly 75% jump the advertised number never mentions